Stroke.
Graeme J Hankey
https://pubmed.ncbi.nlm.nih.gov/27637676Actively Recruiting
Led by Alliance Equiphoria · Updated on 2024-07-31
52
Participants Needed
1
Research Sites
17 weeks
Total Duration
A
Alliance Equiphoria
Lead Sponsor
B
Boehringer Ingelheim
Collaborating Sponsor
Stroke, also known as cerebrovascular accident (CVA), is a leading cause of disability worldwide, with many survivors left with lasting impairments. This research evaluates the effects of hippotherapy, a specialized rehabilitation using horse movement, on patients recovering from stroke, particularly those with moderate disability (Rankin score 3 or higher). The study also aims to assess how this therapy impacts the quality of life for caregivers. The trial compares hippotherapy to conventional outpatient rehabilitation during the recovery phase after hospital discharge. Participants in the study are divided into two groups. One group undergoes a hippotherapy program lasting 22 weeks, including three cycles: a 2-week initial cycle with daily one-hour sessions, followed by a 9-week rest period, then a 1-week daily session cycle, another 9-week rest, and a final 1-week daily session cycle. During rest periods, patients continue their usual outpatient neurorehabilitation. The control group receives standard outpatient rehabilitation such as physiotherapy, occupational therapy, language therapy, and psychological support throughout the program duration. Throughout the study, patients will undergo various clinical tests to measure functional independence, sensorimotor skills, cognitive abilities, stroke severity, and quality of life. Caregivers' burden and quality of life will also be evaluated. The primary outcome focuses on changes in the Functional Independence Measure from baseline to week 22 and up to week 48. Secondary outcomes include assessments like the Modified Rankin Scale, motor recovery evaluations, balance tests, walking distance, and health surveys. The study lasts 48 weeks, including follow-up periods to monitor sustained effects.
CONDITIONS
Neurorehabilitation Through Hippotherapy of a Brain Stroke
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 22 weeks
Participants receive neurorehabilitation either through hippotherapy or conventional outpatient rehabilitation to support recovery of functional independence, sensorimotor and cognitive capacities, and quality of life.
Daily sessions for 2 weeks, then daily sessions for 1 week after a 9-week break, followed by another 1-week daily session after a second 9-week break
Duration - 26 weeks
Participants are monitored after treatment ends to assess long-term changes in functional independence, motor recovery, and quality of life.
Visits at weeks 22 and 48
Total: 1 location
1
Institut Equiphoria
La Canourgue, France, 48500
Actively Recruiting
M
Manuel Gaviria, MD, PhD
D
Didier Smadja, MD, PhD
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Graeme J Hankey
https://pubmed.ncbi.nlm.nih.gov/27637676Ramon Luengo-Fernandez, Nicola L M Paul, Alastair M Gray...
https://pubmed.ncbi.nlm.nih.gov/23920019Danielle Rice, Shannon Janzen, Amanda McIntyre...
https://pubmed.ncbi.nlm.nih.gov/26935115Martin Staudt, Christian Gerloff, Wolfgang Grodd...
https://pubmed.ncbi.nlm.nih.gov/15562409Bruce H Dobkin
https://pubmed.ncbi.nlm.nih.gov/15838110O Raineteau, M E Schwab
https://pubmed.ncbi.nlm.nih.gov/11283749Albert C Lo, Peter D Guarino, Lorie G Richards...
https://pubmed.ncbi.nlm.nih.gov/20400552Yue X Shi, Jin H Tian, Ke H Yang...
https://pubmed.ncbi.nlm.nih.gov/21621674Stephanie A Combs, Eric L Dugan, Miranda Passmore...
https://pubmed.ncbi.nlm.nih.gov/21112434Hélène Viruega, Inès Gaillard, Laura Briatte...
https://pubmed.ncbi.nlm.nih.gov/32384678